Business
Neoleukin Therapeutics Announces Multiple Presentations at American Association for Cancer Research (AACR) Annual Meeting
SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated
About this update from Neurogene Inc.
[{"type":"text","content":"SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced three presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place April 8-13, 2022 in New Orleans, Louisiana. “The upcoming AACR presentations provide additional preclinical data demonstrating the potential for NL-201 to treat hematologic cancers as well as synergy when NL-201 is combined with radiation therapy,” said Jonathan Drachman, M.D., Chief Executive Officer of Neoleukin. “These compelling findings suggest that NL-201 could benefit patients broadly across many indications and in combination with a wide variety of standard-of-care agents.” Poster Presentations: NL-201, a de novo agonist of IL-2 and IL-15 receptors, demonstrates antitumor activity in preclinical B cell lymphoma models Session Title: Immunomodulatory Agents and Interventions 3Date and Time: Wednesday, April 13, 2022, 9:00 a.m. to 12:30 p.m CSTLocation: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 38Poster Board Number: 7Abstract Number: 4227 NL-201, a de novo engineered IL2/IL15 mimic, synergizes with radiation to generate potent antitumor immunity Session Category: ImmunologySession Title: Immunomodulatory Agents and Interventions 1Date and Time: Monday Apr 11, 2022, 1:30 p.m. to 5:00 p.m. CSTLocation: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 38Poster Board Number: 4Abstract Number: 2067 A first-in-human Phase 1 study of NL-201 in patients with relapsed or refractory cancer Session Title: Phase I Trials in Progress 2Date and Time: Wednesday, April 13, 2022, 9:00 a.m. to 12:30 p.m. CSTLocation: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 35Poster Board Number: 11Abstract Number: CT250 About Neoleukin Therapeutics, Inc. Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Neoleukin’s lead product candidate, NL-201, is ...